nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CYP3A4—bone cancer	0.926	1	CbGaD
Fesoterodine—Dry cough—Methotrexate—bone cancer	0.00381	0.0763	CcSEcCtD
Fesoterodine—Obstructive airways disorder—Methotrexate—bone cancer	0.0026	0.052	CcSEcCtD
Fesoterodine—Disopyramide—CYP3A4—bone cancer	0.00165	0.5	CrCbGaD
Fesoterodine—Tolterodine—CYP3A4—bone cancer	0.00165	0.5	CrCbGaD
Fesoterodine—Infection—Carboplatin—bone cancer	0.0013	0.026	CcSEcCtD
Fesoterodine—Face oedema—Cisplatin—bone cancer	0.000753	0.0151	CcSEcCtD
Fesoterodine—Abdominal discomfort—Cisplatin—bone cancer	0.000646	0.0129	CcSEcCtD
Fesoterodine—Hepatic enzyme increased—Methotrexate—bone cancer	0.000624	0.0125	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Cisplatin—bone cancer	0.000569	0.0114	CcSEcCtD
Fesoterodine—Urinary tract disorder—Cisplatin—bone cancer	0.000533	0.0107	CcSEcCtD
Fesoterodine—Urethral disorder—Cisplatin—bone cancer	0.000529	0.0106	CcSEcCtD
Fesoterodine—Dry eye—Epirubicin—bone cancer	0.00051	0.0102	CcSEcCtD
Fesoterodine—Eye disorder—Cisplatin—bone cancer	0.000504	0.0101	CcSEcCtD
Fesoterodine—Cardiac disorder—Cisplatin—bone cancer	0.000501	0.01	CcSEcCtD
Fesoterodine—Mediastinal disorder—Cisplatin—bone cancer	0.000486	0.00973	CcSEcCtD
Fesoterodine—Dry eye—Doxorubicin—bone cancer	0.000472	0.00944	CcSEcCtD
Fesoterodine—Flatulence—Cisplatin—bone cancer	0.000463	0.00926	CcSEcCtD
Fesoterodine—Vision blurred—Cisplatin—bone cancer	0.000443	0.00886	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000397	0.00795	CcSEcCtD
Fesoterodine—Face oedema—Epirubicin—bone cancer	0.000387	0.00774	CcSEcCtD
Fesoterodine—Infection—Cisplatin—bone cancer	0.000381	0.00762	CcSEcCtD
Fesoterodine—Nervous system disorder—Cisplatin—bone cancer	0.000376	0.00753	CcSEcCtD
Fesoterodine—Tachycardia—Cisplatin—bone cancer	0.000374	0.00749	CcSEcCtD
Fesoterodine—Skin disorder—Cisplatin—bone cancer	0.000372	0.00745	CcSEcCtD
Fesoterodine—Dry skin—Epirubicin—bone cancer	0.000367	0.00735	CcSEcCtD
Fesoterodine—Abdominal pain upper—Epirubicin—bone cancer	0.000366	0.00732	CcSEcCtD
Fesoterodine—Face oedema—Doxorubicin—bone cancer	0.000358	0.00716	CcSEcCtD
Fesoterodine—Abdominal discomfort—Methotrexate—bone cancer	0.000355	0.0071	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000353	0.00707	CcSEcCtD
Fesoterodine—Dysuria—Methotrexate—bone cancer	0.000346	0.00692	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Methotrexate—bone cancer	0.000344	0.00688	CcSEcCtD
Fesoterodine—Dry skin—Doxorubicin—bone cancer	0.00034	0.0068	CcSEcCtD
Fesoterodine—Abdominal pain upper—Doxorubicin—bone cancer	0.000339	0.00678	CcSEcCtD
Fesoterodine—Angina pectoris—Epirubicin—bone cancer	0.000337	0.00675	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000331	0.00662	CcSEcCtD
Fesoterodine—Infestation—Methotrexate—bone cancer	0.00033	0.0066	CcSEcCtD
Fesoterodine—Infestation NOS—Methotrexate—bone cancer	0.00033	0.0066	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000327	0.00654	CcSEcCtD
Fesoterodine—Dysuria—Epirubicin—bone cancer	0.000324	0.00648	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Epirubicin—bone cancer	0.000322	0.00644	CcSEcCtD
Fesoterodine—Feeling abnormal—Cisplatin—bone cancer	0.000316	0.00632	CcSEcCtD
Fesoterodine—Angina pectoris—Doxorubicin—bone cancer	0.000312	0.00625	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Methotrexate—bone cancer	0.000312	0.00624	CcSEcCtD
Fesoterodine—Infestation—Epirubicin—bone cancer	0.000309	0.00618	CcSEcCtD
Fesoterodine—Infestation NOS—Epirubicin—bone cancer	0.000309	0.00618	CcSEcCtD
Fesoterodine—Urinary tract infection—Epirubicin—bone cancer	0.0003	0.00601	CcSEcCtD
Fesoterodine—Dysuria—Doxorubicin—bone cancer	0.0003	0.006	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000298	0.00596	CcSEcCtD
Fesoterodine—Urinary tract disorder—Methotrexate—bone cancer	0.000293	0.00585	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Epirubicin—bone cancer	0.000292	0.00584	CcSEcCtD
Fesoterodine—Urethral disorder—Methotrexate—bone cancer	0.00029	0.00581	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—bone cancer	0.000286	0.00572	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—bone cancer	0.000286	0.00572	CcSEcCtD
Fesoterodine—Hypersensitivity—Cisplatin—bone cancer	0.000283	0.00565	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—bone cancer	0.000278	0.00556	CcSEcCtD
Fesoterodine—Eye disorder—Methotrexate—bone cancer	0.000277	0.00554	CcSEcCtD
Fesoterodine—Asthenia—Cisplatin—bone cancer	0.000275	0.00551	CcSEcCtD
Fesoterodine—Cardiac disorder—Methotrexate—bone cancer	0.000275	0.0055	CcSEcCtD
Fesoterodine—Urinary tract disorder—Epirubicin—bone cancer	0.000274	0.00548	CcSEcCtD
Fesoterodine—Oedema peripheral—Epirubicin—bone cancer	0.000273	0.00546	CcSEcCtD
Fesoterodine—Urethral disorder—Epirubicin—bone cancer	0.000272	0.00544	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—bone cancer	0.00027	0.00541	CcSEcCtD
Fesoterodine—Mediastinal disorder—Methotrexate—bone cancer	0.000267	0.00534	CcSEcCtD
Fesoterodine—Diarrhoea—Cisplatin—bone cancer	0.000262	0.00525	CcSEcCtD
Fesoterodine—Mental disorder—Methotrexate—bone cancer	0.000259	0.00519	CcSEcCtD
Fesoterodine—Eye disorder—Epirubicin—bone cancer	0.000259	0.00518	CcSEcCtD
Fesoterodine—Cardiac disorder—Epirubicin—bone cancer	0.000257	0.00515	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—bone cancer	0.000253	0.00507	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—bone cancer	0.000253	0.00506	CcSEcCtD
Fesoterodine—Dysgeusia—Methotrexate—bone cancer	0.000252	0.00505	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—bone cancer	0.000251	0.00503	CcSEcCtD
Fesoterodine—Mediastinal disorder—Epirubicin—bone cancer	0.00025	0.005	CcSEcCtD
Fesoterodine—Back pain—Methotrexate—bone cancer	0.000249	0.00499	CcSEcCtD
Fesoterodine—Vision blurred—Methotrexate—bone cancer	0.000243	0.00486	CcSEcCtD
Fesoterodine—Mental disorder—Epirubicin—bone cancer	0.000243	0.00486	CcSEcCtD
Fesoterodine—Rash—Cisplatin—bone cancer	0.000242	0.00484	CcSEcCtD
Fesoterodine—Dermatitis—Cisplatin—bone cancer	0.000242	0.00483	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—bone cancer	0.00024	0.0048	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—bone cancer	0.000238	0.00476	CcSEcCtD
Fesoterodine—Flatulence—Epirubicin—bone cancer	0.000238	0.00476	CcSEcCtD
Fesoterodine—Dysgeusia—Epirubicin—bone cancer	0.000236	0.00473	CcSEcCtD
Fesoterodine—Back pain—Epirubicin—bone cancer	0.000233	0.00467	CcSEcCtD
Fesoterodine—Vertigo—Methotrexate—bone cancer	0.000232	0.00464	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—bone cancer	0.000231	0.00463	CcSEcCtD
Fesoterodine—Nausea—Cisplatin—bone cancer	0.000228	0.00456	CcSEcCtD
Fesoterodine—Vision blurred—Epirubicin—bone cancer	0.000227	0.00455	CcSEcCtD
Fesoterodine—Cough—Methotrexate—bone cancer	0.000225	0.0045	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—bone cancer	0.000225	0.0045	CcSEcCtD
Fesoterodine—Flatulence—Doxorubicin—bone cancer	0.00022	0.0044	CcSEcCtD
Fesoterodine—Chest pain—Methotrexate—bone cancer	0.00022	0.00439	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—bone cancer	0.000219	0.00438	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000218	0.00436	CcSEcCtD
Fesoterodine—Vertigo—Epirubicin—bone cancer	0.000217	0.00434	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—bone cancer	0.000216	0.00432	CcSEcCtD
Fesoterodine—Palpitations—Epirubicin—bone cancer	0.000213	0.00427	CcSEcCtD
Fesoterodine—Confusional state—Methotrexate—bone cancer	0.000212	0.00425	CcSEcCtD
Fesoterodine—Cough—Epirubicin—bone cancer	0.000211	0.00421	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—bone cancer	0.00021	0.00421	CcSEcCtD
Fesoterodine—Infection—Methotrexate—bone cancer	0.000209	0.00418	CcSEcCtD
Fesoterodine—Nervous system disorder—Methotrexate—bone cancer	0.000206	0.00413	CcSEcCtD
Fesoterodine—Chest pain—Epirubicin—bone cancer	0.000205	0.00411	CcSEcCtD
Fesoterodine—Skin disorder—Methotrexate—bone cancer	0.000204	0.00409	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000204	0.00408	CcSEcCtD
Fesoterodine—Dry mouth—Epirubicin—bone cancer	0.000201	0.00402	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—bone cancer	0.000201	0.00401	CcSEcCtD
Fesoterodine—Confusional state—Epirubicin—bone cancer	0.000199	0.00397	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—bone cancer	0.000197	0.00395	CcSEcCtD
Fesoterodine—Infection—Epirubicin—bone cancer	0.000196	0.00391	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—bone cancer	0.000195	0.0039	CcSEcCtD
Fesoterodine—Nervous system disorder—Epirubicin—bone cancer	0.000193	0.00386	CcSEcCtD
Fesoterodine—Tachycardia—Epirubicin—bone cancer	0.000192	0.00385	CcSEcCtD
Fesoterodine—Skin disorder—Epirubicin—bone cancer	0.000191	0.00383	CcSEcCtD
Fesoterodine—Insomnia—Methotrexate—bone cancer	0.00019	0.00381	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—bone cancer	0.00019	0.0038	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000189	0.00378	CcSEcCtD
Fesoterodine—Somnolence—Methotrexate—bone cancer	0.000187	0.00374	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—bone cancer	0.000186	0.00372	CcSEcCtD
Fesoterodine—Dyspepsia—Methotrexate—bone cancer	0.000185	0.00371	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—bone cancer	0.000184	0.00368	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000182	0.00364	CcSEcCtD
Fesoterodine—Fatigue—Methotrexate—bone cancer	0.000181	0.00363	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—bone cancer	0.000181	0.00362	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—bone cancer	0.000179	0.00358	CcSEcCtD
Fesoterodine—Insomnia—Epirubicin—bone cancer	0.000178	0.00356	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—bone cancer	0.000178	0.00356	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—bone cancer	0.000177	0.00354	CcSEcCtD
Fesoterodine—Somnolence—Epirubicin—bone cancer	0.000175	0.0035	CcSEcCtD
Fesoterodine—Feeling abnormal—Methotrexate—bone cancer	0.000173	0.00347	CcSEcCtD
Fesoterodine—Dyspepsia—Epirubicin—bone cancer	0.000173	0.00347	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Methotrexate—bone cancer	0.000172	0.00344	CcSEcCtD
Fesoterodine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000171	0.00833	CbGpPWpGaD
Fesoterodine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00017	0.0034	CcSEcCtD
Fesoterodine—Fatigue—Epirubicin—bone cancer	0.00017	0.0034	CcSEcCtD
Fesoterodine—Constipation—Epirubicin—bone cancer	0.000168	0.00337	CcSEcCtD
Fesoterodine—Urticaria—Methotrexate—bone cancer	0.000167	0.00335	CcSEcCtD
Fesoterodine—Abdominal pain—Methotrexate—bone cancer	0.000166	0.00333	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—bone cancer	0.000165	0.0033	CcSEcCtD
Fesoterodine—Feeling abnormal—Epirubicin—bone cancer	0.000162	0.00325	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—bone cancer	0.000162	0.00324	CcSEcCtD
Fesoterodine—CHRM4—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000162	0.00786	CbGpPWpGaD
Fesoterodine—Gastrointestinal pain—Epirubicin—bone cancer	0.000161	0.00322	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—bone cancer	0.00016	0.00321	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000157	0.00315	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—bone cancer	0.000157	0.00314	CcSEcCtD
Fesoterodine—Urticaria—Epirubicin—bone cancer	0.000156	0.00313	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—bone cancer	0.000156	0.00312	CcSEcCtD
Fesoterodine—Abdominal pain—Epirubicin—bone cancer	0.000156	0.00312	CcSEcCtD
Fesoterodine—Hypersensitivity—Methotrexate—bone cancer	0.000155	0.0031	CcSEcCtD
Fesoterodine—CHRM5—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000155	0.00753	CbGpPWpGaD
Fesoterodine—Asthenia—Methotrexate—bone cancer	0.000151	0.00302	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—bone cancer	0.00015	0.003	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000149	0.00298	CcSEcCtD
Fesoterodine—Pruritus—Methotrexate—bone cancer	0.000149	0.00298	CcSEcCtD
Fesoterodine—Hypersensitivity—Epirubicin—bone cancer	0.000145	0.0029	CcSEcCtD
Fesoterodine—CHRM3—Integration of energy metabolism—GNA11—bone cancer	0.000145	0.00704	CbGpPWpGaD
Fesoterodine—Urticaria—Doxorubicin—bone cancer	0.000145	0.0029	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—bone cancer	0.000144	0.00288	CcSEcCtD
Fesoterodine—Diarrhoea—Methotrexate—bone cancer	0.000144	0.00288	CcSEcCtD
Fesoterodine—Asthenia—Epirubicin—bone cancer	0.000141	0.00283	CcSEcCtD
Fesoterodine—CHRM1—G alpha (q) signalling events—GRM1—bone cancer	0.000141	0.00686	CbGpPWpGaD
Fesoterodine—CHRM3—G alpha (q) signalling events—GRM1—bone cancer	0.000141	0.00684	CbGpPWpGaD
Fesoterodine—Pruritus—Epirubicin—bone cancer	0.000139	0.00279	CcSEcCtD
Fesoterodine—Dizziness—Methotrexate—bone cancer	0.000139	0.00278	CcSEcCtD
Fesoterodine—Diarrhoea—Epirubicin—bone cancer	0.000135	0.0027	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—bone cancer	0.000134	0.00269	CcSEcCtD
Fesoterodine—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	0.000134	0.0065	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	0.000134	0.0065	CbGpPWpGaD
Fesoterodine—Rash—Methotrexate—bone cancer	0.000133	0.00266	CcSEcCtD
Fesoterodine—Dermatitis—Methotrexate—bone cancer	0.000133	0.00265	CcSEcCtD
Fesoterodine—Headache—Methotrexate—bone cancer	0.000132	0.00264	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—bone cancer	0.000131	0.00262	CcSEcCtD
Fesoterodine—Dizziness—Epirubicin—bone cancer	0.00013	0.00261	CcSEcCtD
Fesoterodine—CHRM5—G alpha (q) signalling events—GNA11—bone cancer	0.000129	0.00628	CbGpPWpGaD
Fesoterodine—Pruritus—Doxorubicin—bone cancer	0.000129	0.00258	CcSEcCtD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000126	0.00613	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000126	0.00612	CbGpPWpGaD
Fesoterodine—Nausea—Methotrexate—bone cancer	0.000125	0.0025	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—bone cancer	0.000125	0.00249	CcSEcCtD
Fesoterodine—Rash—Epirubicin—bone cancer	0.000124	0.00248	CcSEcCtD
Fesoterodine—Dermatitis—Epirubicin—bone cancer	0.000124	0.00248	CcSEcCtD
Fesoterodine—Headache—Epirubicin—bone cancer	0.000123	0.00247	CcSEcCtD
Fesoterodine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000122	0.00593	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—GRM4—bone cancer	0.000122	0.00592	CbGpPWpGaD
Fesoterodine—Dizziness—Doxorubicin—bone cancer	0.00012	0.00241	CcSEcCtD
Fesoterodine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00012	0.00585	CbGpPWpGaD
Fesoterodine—Nausea—Epirubicin—bone cancer	0.000117	0.00234	CcSEcCtD
Fesoterodine—CHRM5—GPCR ligand binding—GRM4—bone cancer	0.000117	0.00567	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000116	0.00561	CbGpPWpGaD
Fesoterodine—Rash—Doxorubicin—bone cancer	0.000115	0.0023	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—bone cancer	0.000115	0.0023	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—bone cancer	0.000114	0.00228	CcSEcCtD
Fesoterodine—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000109	0.0053	CbGpPWpGaD
Fesoterodine—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000109	0.00528	CbGpPWpGaD
Fesoterodine—Nausea—Doxorubicin—bone cancer	0.000108	0.00217	CcSEcCtD
Fesoterodine—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000108	0.00523	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—GRM1—bone cancer	0.000106	0.00513	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—GRM1—bone cancer	0.000101	0.00491	CbGpPWpGaD
Fesoterodine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.9e-05	0.00481	CbGpPWpGaD
Fesoterodine—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	9.1e-05	0.00442	CbGpPWpGaD
Fesoterodine—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	9.07e-05	0.00441	CbGpPWpGaD
Fesoterodine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	8.89e-05	0.00432	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—GNA11—bone cancer	8.59e-05	0.00417	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—EZH2—bone cancer	8.55e-05	0.00415	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—GRM4—bone cancer	8.21e-05	0.00399	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—GRM4—bone cancer	8.19e-05	0.00398	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	8.14e-05	0.00395	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	8.11e-05	0.00394	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—GRM4—bone cancer	8.11e-05	0.00394	CbGpPWpGaD
Fesoterodine—CHRM4—Regulation of Actin Cytoskeleton—BRAF—bone cancer	8.05e-05	0.00391	CbGpPWpGaD
Fesoterodine—CHRM5—Regulation of Actin Cytoskeleton—BRAF—bone cancer	7.71e-05	0.00374	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—SMO—bone cancer	7.44e-05	0.00361	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.28e-05	0.00353	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—SMO—bone cancer	7.13e-05	0.00346	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—GRM1—bone cancer	7.12e-05	0.00346	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—GRM1—bone cancer	7.1e-05	0.00345	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—GRM1—bone cancer	7.03e-05	0.00341	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—RGS1—bone cancer	6.88e-05	0.00334	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—GRM4—bone cancer	6.88e-05	0.00334	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—GRM4—bone cancer	6.59e-05	0.0032	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—RGS1—bone cancer	6.59e-05	0.0032	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—RGS1—bone cancer	6.25e-05	0.00304	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—GRM4—bone cancer	6.25e-05	0.00304	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.19e-05	0.00301	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—GRM4—bone cancer	5.99e-05	0.00291	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—RGS1—bone cancer	5.99e-05	0.00291	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—GRM1—bone cancer	5.97e-05	0.0029	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—GRM1—bone cancer	5.72e-05	0.00278	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.63e-05	0.00274	CbGpPWpGaD
Fesoterodine—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	5.43e-05	0.00264	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—GRM1—bone cancer	5.42e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	5.41e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	5.36e-05	0.0026	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—NDUFA12—bone cancer	5.27e-05	0.00256	CbGpPWpGaD
Fesoterodine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.26e-05	0.00255	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—GRM1—bone cancer	5.19e-05	0.00252	CbGpPWpGaD
Fesoterodine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.18e-05	0.00252	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.13e-05	0.00249	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.06e-05	0.00246	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—SMO—bone cancer	5.02e-05	0.00244	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—SMO—bone cancer	5e-05	0.00243	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—SMO—bone cancer	4.95e-05	0.00241	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—CDK4—bone cancer	4.83e-05	0.00234	CbGpPWpGaD
Fesoterodine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.8e-05	0.00233	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—GRM4—bone cancer	4.64e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—RGS1—bone cancer	4.64e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—RGS1—bone cancer	4.63e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—GRM4—bone cancer	4.63e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM4—Regulation of Actin Cytoskeleton—EGFR—bone cancer	4.61e-05	0.00224	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—RGS1—bone cancer	4.58e-05	0.00223	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—GRM4—bone cancer	4.58e-05	0.00223	CbGpPWpGaD
Fesoterodine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.54e-05	0.0022	CbGpPWpGaD
Fesoterodine—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.5e-05	0.00218	CbGpPWpGaD
Fesoterodine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.43e-05	0.00215	CbGpPWpGaD
Fesoterodine—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	4.41e-05	0.00214	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—NT5C3A—bone cancer	4.37e-05	0.00212	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.29e-05	0.00208	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.28e-05	0.00208	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—GRM4—bone cancer	4.21e-05	0.00205	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—RGS1—bone cancer	4.21e-05	0.00205	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—RGS1—bone cancer	4.2e-05	0.00204	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—GRM4—bone cancer	4.2e-05	0.00204	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—RGS1—bone cancer	4.16e-05	0.00202	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—GRM4—bone cancer	4.16e-05	0.00202	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—GRM1—bone cancer	4.02e-05	0.00195	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—GRM1—bone cancer	4.01e-05	0.00195	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—GRM1—bone cancer	3.97e-05	0.00193	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—GNA11—bone cancer	3.85e-05	0.00187	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—SMO—bone cancer	3.82e-05	0.00185	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	3.76e-05	0.00183	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—GRM4—bone cancer	3.69e-05	0.00179	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—RGS1—bone cancer	3.69e-05	0.00179	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.69e-05	0.00179	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—GNA11—bone cancer	3.68e-05	0.00179	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—SMO—bone cancer	3.66e-05	0.00178	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—GRM1—bone cancer	3.65e-05	0.00178	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—GRM1—bone cancer	3.64e-05	0.00177	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—GRM1—bone cancer	3.61e-05	0.00175	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—GRM4—bone cancer	3.54e-05	0.00172	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—RGS1—bone cancer	3.54e-05	0.00172	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—GNA11—bone cancer	3.49e-05	0.0017	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—IL3—bone cancer	3.49e-05	0.00169	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—GNA11—bone cancer	3.34e-05	0.00162	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NDUFA12—bone cancer	3.34e-05	0.00162	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—IL3—bone cancer	3.34e-05	0.00162	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.29e-05	0.0016	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—GRM1—bone cancer	3.2e-05	0.00156	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.18e-05	0.00154	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL3—bone cancer	3.17e-05	0.00154	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NDUFA12—bone cancer	3.15e-05	0.00153	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—JUN—bone cancer	3.11e-05	0.00151	CbGpPWpGaD
Fesoterodine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.11e-05	0.00151	CbGpPWpGaD
Fesoterodine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.1e-05	0.0015	CbGpPWpGaD
Fesoterodine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.07e-05	0.00149	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—GRM1—bone cancer	3.07e-05	0.00149	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL3—bone cancer	3.03e-05	0.00147	CbGpPWpGaD
Fesoterodine—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.94e-05	0.00143	CbGpPWpGaD
Fesoterodine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.9e-05	0.00141	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NT5C3A—bone cancer	2.77e-05	0.00135	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NT5C3A—bone cancer	2.61e-05	0.00127	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—GNA11—bone cancer	2.59e-05	0.00126	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—GNA11—bone cancer	2.58e-05	0.00126	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—SMO—bone cancer	2.57e-05	0.00125	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—SMO—bone cancer	2.57e-05	0.00125	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—GNA11—bone cancer	2.56e-05	0.00124	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—SMO—bone cancer	2.54e-05	0.00123	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—GRM4—bone cancer	2.49e-05	0.00121	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RGS1—bone cancer	2.49e-05	0.00121	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RGS1—bone cancer	2.48e-05	0.00121	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—GRM4—bone cancer	2.48e-05	0.00121	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RGS1—bone cancer	2.46e-05	0.00119	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—GRM4—bone cancer	2.46e-05	0.00119	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.36e-05	0.00115	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—GNA11—bone cancer	2.35e-05	0.00114	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—IL3—bone cancer	2.35e-05	0.00114	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—GNA11—bone cancer	2.35e-05	0.00114	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—IL3—bone cancer	2.34e-05	0.00114	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—GNA11—bone cancer	2.32e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—IL3—bone cancer	2.32e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.32e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.31e-05	0.00112	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.27e-05	0.0011	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SMO—bone cancer	2.26e-05	0.0011	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SMO—bone cancer	2.16e-05	0.00105	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—GRM1—bone cancer	2.16e-05	0.00105	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—GRM1—bone cancer	2.15e-05	0.00105	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL3—bone cancer	2.13e-05	0.00104	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—GRM1—bone cancer	2.13e-05	0.00104	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL3—bone cancer	2.13e-05	0.00103	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL3—bone cancer	2.11e-05	0.00102	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—GNA11—bone cancer	2.06e-05	0.001	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NDUFA12—bone cancer	2.06e-05	0.001	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—TP53—bone cancer	2.05e-05	0.000997	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.05e-05	0.000996	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—GNA11—bone cancer	1.98e-05	0.00096	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—ATF1—bone cancer	1.92e-05	0.000932	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—ENO2—bone cancer	1.91e-05	0.000929	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL3—bone cancer	1.87e-05	0.000909	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—ATF1—bone cancer	1.84e-05	0.000892	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL3—bone cancer	1.79e-05	0.00087	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—DHFR—bone cancer	1.77e-05	0.000862	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.71e-05	0.000829	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—GNA11—bone cancer	1.66e-05	0.000806	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.61e-05	0.000783	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TGFBR2—bone cancer	1.6e-05	0.000777	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TGFBR2—bone cancer	1.53e-05	0.000744	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SMO—bone cancer	1.52e-05	0.000739	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SMO—bone cancer	1.52e-05	0.000737	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IGF1R—bone cancer	1.51e-05	0.000731	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—CYP3A4—bone cancer	1.5e-05	0.00073	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SMO—bone cancer	1.5e-05	0.000729	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IGF1R—bone cancer	1.44e-05	0.0007	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—GNA11—bone cancer	1.39e-05	0.000676	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—GNA11—bone cancer	1.39e-05	0.000674	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—GNA11—bone cancer	1.37e-05	0.000667	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.35e-05	0.000657	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ATF1—bone cancer	1.29e-05	0.000628	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ATF1—bone cancer	1.29e-05	0.000626	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—GSTP1—bone cancer	1.29e-05	0.000625	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ATF1—bone cancer	1.28e-05	0.00062	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL3—bone cancer	1.26e-05	0.000613	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL3—bone cancer	1.26e-05	0.000611	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL3—bone cancer	1.24e-05	0.000605	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ENO2—bone cancer	1.21e-05	0.00059	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ENO2—bone cancer	1.14e-05	0.000556	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—DHFR—bone cancer	1.13e-05	0.000547	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KIT—bone cancer	1.09e-05	0.00053	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TGFBR2—bone cancer	1.08e-05	0.000524	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TGFBR2—bone cancer	1.08e-05	0.000522	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	1.06e-05	0.000517	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—DHFR—bone cancer	1.06e-05	0.000515	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GNA11—bone cancer	1.05e-05	0.000511	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KIT—bone cancer	1.05e-05	0.000508	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—BRAF—bone cancer	1.03e-05	0.000498	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF1R—bone cancer	1.01e-05	0.000493	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF1R—bone cancer	1.01e-05	0.000491	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF1R—bone cancer	1e-05	0.000487	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—EGFR—bone cancer	9.94e-06	0.000483	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GNA11—bone cancer	9.92e-06	0.000482	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—BRAF—bone cancer	9.83e-06	0.000477	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CYP3A4—bone cancer	9.54e-06	0.000463	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—EGFR—bone cancer	9.52e-06	0.000463	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYP3A4—bone cancer	8.99e-06	0.000437	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MDM2—bone cancer	8.6e-06	0.000418	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MDM2—bone cancer	8.23e-06	0.0004	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTP1—bone cancer	8.16e-06	0.000396	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTP1—bone cancer	7.69e-06	0.000373	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ENO2—bone cancer	7.48e-06	0.000363	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—JUN—bone cancer	7.47e-06	0.000363	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KIT—bone cancer	7.36e-06	0.000358	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KIT—bone cancer	7.34e-06	0.000356	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—bone cancer	7.27e-06	0.000353	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KIT—bone cancer	7.27e-06	0.000353	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—JUN—bone cancer	7.16e-06	0.000348	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—bone cancer	6.96e-06	0.000338	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—DHFR—bone cancer	6.94e-06	0.000337	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—BRAF—bone cancer	6.92e-06	0.000336	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—BRAF—bone cancer	6.9e-06	0.000335	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BRAF—bone cancer	6.83e-06	0.000332	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—EGFR—bone cancer	6.71e-06	0.000326	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—EGFR—bone cancer	6.68e-06	0.000325	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—bone cancer	6.66e-06	0.000324	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—EGFR—bone cancer	6.62e-06	0.000322	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GNA11—bone cancer	6.48e-06	0.000315	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EGFR—bone cancer	5.87e-06	0.000285	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MDM2—bone cancer	5.8e-06	0.000282	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MDM2—bone cancer	5.78e-06	0.000281	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MDM2—bone cancer	5.72e-06	0.000278	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EGFR—bone cancer	5.63e-06	0.000273	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JUN—bone cancer	5.04e-06	0.000245	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—bone cancer	5.03e-06	0.000244	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JUN—bone cancer	5.02e-06	0.000244	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JUN—bone cancer	4.97e-06	0.000242	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—bone cancer	4.93e-06	0.00024	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—bone cancer	4.9e-06	0.000238	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—bone cancer	4.89e-06	0.000237	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—bone cancer	4.84e-06	0.000235	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—bone cancer	4.72e-06	0.000229	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—bone cancer	4.23e-06	0.000205	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—bone cancer	3.98e-06	0.000193	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGFR—bone cancer	3.96e-06	0.000192	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGFR—bone cancer	3.95e-06	0.000192	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGFR—bone cancer	3.91e-06	0.00019	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—bone cancer	3.33e-06	0.000162	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—bone cancer	3.32e-06	0.000161	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—bone cancer	3.28e-06	0.000159	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—bone cancer	2.6e-06	0.000127	CbGpPWpGaD
